ストックスクリーナーアプリを入手
1.09
0.00%
0.00
アフターアワーズ：
1.11
0.02
+1.83%
前日終値:
$1.09
開ける：
$1.1
24時間の取引高:
23,258
Relative Volume:
0.81
時価総額：
$3.52M
収益：
-
当期純損益:
$-9.60M
株価収益率:
-0.3449
EPS:
-3.16
ネットキャッシュフロー:
$-8.96M
1週間 パフォーマンス:
+2.83%
1か月 パフォーマンス:
+0.93%
6か月 パフォーマンス:
-19.85%
1年 パフォーマンス:
-21.58%
1日の値動き範囲:
$1.07
$1.125
1週間の範囲:
$1.047
$1.125
52週間の値動き範囲:
$0.91
$1.75
Artelo Biosciences Inc Stock (ARTL) Company Profile
名前
Artelo Biosciences Inc
セクター
電話
858-925-7049
住所
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
ARTL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.09 | 3.52M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-02-12 | 開始されました | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc (ARTL) 最新ニュース
Artelo Biosciences Holds Annual Meeting; Directors Re-Elected and Independent Auditor Appointment Ratified - Defense World
Artelo Biosciences stock hits 52-week low at $0.97 By Investing.com - Investing.com Canada
Artelo Biosciences stock hits 52-week low at $0.97 - Investing.com
Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia - Yahoo Finance
Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
California Biopharma Shows Promising Phase 1 Data - Streetwise Reports
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia - The Manila Times
Artelo's Cancer Drug Shows Breakthrough Results: 67% of Patients Reverse Weight Loss in Phase 1 Trial - StockTitan
Artelo reports positive preliminary data for cancer anorexia drug - Investing.com
Artelo Biosciences (ARTL) Stock Surges 5% Amid Strong Buy Ratings - GuruFocus.com
Artelo Biosciences (ARTL) Shares Drop Amidst Biotech Sector Move - GuruFocus.com
Artelo Biosciences (ARTL) Stock Surges Amid Strong Buy Ratings - GuruFocus.com
Artelo Biosciences to Present Key Drug Development Data at Major Cannabinoid Summit | ARTL Stock News - StockTitan
HC Wainwright Has Negative Outlook of ARTL FY2024 Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World
Cancer Anorexia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals - The Globe and Mail
Artelo Biosciences Inc. (ARTL) Quarterly 10-Q Report - Quartz
Artelo Biosciences Reports Q3 2024 Financials and Progress - TipRanks
Artelo Biosciences (ARTL) Stock Dips Amidst Financial Report - GuruFocus.com
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium - The Manila Times
Artelo's Pain Drug Outperforms Naproxen in Key Study; FDA Clears Phase 1 Trial | ARTL Stock News - StockTitan
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma - The Manila Times
Artelo Bio Slashes Losses 54%, Advances Pipeline with Multiple Clinical Trials Ahead | ARTL Stock News - StockTitan
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Artelo Biosciences (ARTL) Shares Dive Amidst Biotech Sector Move - GuruFocus.com
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - The Manila Times
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program - StockTitan
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's 'Preclinical Screening Platform for Pain” Program - The Manila Times
Artelo Biosciences (ARTL) Stock Surges Amid Bullish Analyst Rati - GuruFocus.com
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th - The Manila Times
How doctors hope new cannabis drug will help cancer patients gain weight - inews
FABP5 inhibitor ART-26.12 exhibits activity in psoriasis models - BioWorld Online
Artelo Biosciences shares initiated with Buy by EF Hutton - Investing.com UK
EF Hutton Initiates Coverage of Artelo Biosciences (ARTL) with Buy Recommendation - MSN
Equities Analysts Offer Predictions for Stitch Fix, Inc.’s Q1 2025 Earnings (NASDAQ:SFIX) - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update - Defense World
Anorexia Nervosa Market Expected to Experience Major Growth - openPR
ARTL stock touches 52-week low at $1.12 amid market challenges - Investing.com Canada
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024 - MSN
ARTLW (Artelo Biosciences) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
ARTL (Artelo Biosciences) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
ARTL (Artelo Biosciences) EV-to-Revenue : (As of Aug. 17, 2024) - GuruFocus.com
HC Wainwright Weighs in on Artelo Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:ARTL) - Defense World
Artelo Biosciences’ (ARTL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Artelo Biosciences (NASDAQ:ARTL) Announces Earnings Results - Defense World
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update - BioSpace
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Up 3,808.3% in July - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 91.5% in July - Defense World
New drug to control pain related to cancer treatment originally developed at Stony Brook gets FDA clearance - TBR News Media
UK life sciences can lead the way in global cannabinoid R&D says CRDG report - European Pharmaceutical Manufacturer
Artelo Biosciences Inc (ARTL) 財務データ
収益
当期純利益
現金流量
EPS
0.60%
2.24%
大文字化:
|
ボリューム (24 時間):